Abeona Therapeutics IncのEBITDA margin
Abeona Therapeutics IncのEBITDA marginは何ですか。
Abeona Therapeutics IncのEBITDA marginは-977.33%です。
EBITDA marginの定義は何ですか。
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
NASDAQのセクタHealth CareにおけるEBITDA marginの企業と比べるAbeona Therapeutics Inc
Abeona Therapeutics Incは何をしますか。
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Incと類似のebitda margin
- AdrabbitのEBITDA marginは-1,007.72%です。
- Oventus MedicalのEBITDA marginは-1,005.03%です。
- Wins FinanceのEBITDA marginは-997.38%です。
- Kairos MineralsのEBITDA marginは-995.30%です。
- Linius TechnologiesのEBITDA marginは-985.68%です。
- Aruma ResourcesのEBITDA marginは-979.66%です。
- Abeona Therapeutics IncのEBITDA marginは-977.33%です。
- Abivax SAのEBITDA marginは-977.30%です。
- AnterixのEBITDA marginは-976.00%です。
- Concert Pharmaceuticals IncのEBITDA marginは-975.28%です。
- PilotのEBITDA marginは-971.94%です。
- De Grey MiningのEBITDA marginは-969.24%です。
- Willow BiosciencesのEBITDA marginは-968.55%です。